These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 31318041)

  • 41. Tofacitinib, a novel JAK3 inhibitor, as a potential cause of distal symmetric polyneuropathy.
    Zeidler C; von Köckritz A; Luger TA; Ständer S; Husstedt IW; Tsianakas A
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):1066-7. PubMed ID: 25787234
    [No Abstract]   [Full Text] [Related]  

  • 42. Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.
    Checchio T; Ahadieh S; Gupta P; Mandema J; Puig L; Wolk R; Valdez H; Tan H; Krishnaswami S; Tallman A; Kaur M; Ito K
    Clin Pharmacol Ther; 2017 Dec; 102(6):1006-1016. PubMed ID: 28480503
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rapid Repigmentation of Vitiligo Using Tofacitinib Plus Low-Dose, Narrowband UV-B Phototherapy.
    Kim SR; Heaton H; Liu LY; King BA
    JAMA Dermatol; 2018 Mar; 154(3):370-371. PubMed ID: 29387870
    [No Abstract]   [Full Text] [Related]  

  • 45. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 46. Tofacitinib therapy for children with severe alopecia areata.
    Dai YX; Chen CC
    J Am Acad Dermatol; 2019 Apr; 80(4):1164-1166. PubMed ID: 30630026
    [No Abstract]   [Full Text] [Related]  

  • 47. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
    Liu LY; Craiglow BG; King BA
    J Am Acad Dermatol; 2018 Feb; 78(2):403-404.e1. PubMed ID: 29108908
    [No Abstract]   [Full Text] [Related]  

  • 48. Successful Treatment of Pyoderma Gangrenosum with Concomitant Tofacitinib and Infliximab.
    Gregory MH; Ciorba MA; Deepak P; Christophi GP
    Inflamm Bowel Dis; 2019 Jun; 25(7):e87-e88. PubMed ID: 30753456
    [No Abstract]   [Full Text] [Related]  

  • 49. Tofacitinib Citrate for the Treatment of Nail Dystrophy Associated With Alopecia Universalis.
    Dhayalan A; King BA
    JAMA Dermatol; 2016 Apr; 152(4):492-3. PubMed ID: 26630079
    [No Abstract]   [Full Text] [Related]  

  • 50. [Tofacitinib].
    Döker S; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2014 May; 139(19):1003-8. PubMed ID: 24782154
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tofacitinib for psoriatic arthritis (PsA) is now approved by the European Commission.
    Rheumatology (Oxford); 2018 Sep; 57(9):e55. PubMed ID: 30137541
    [No Abstract]   [Full Text] [Related]  

  • 52. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia.
    Bilori B; Thota S; Clemente MJ; Patel B; Jerez A; Afable Ii M; Maciejewski JP
    Leukemia; 2015 Dec; 29(12):2427-9. PubMed ID: 26449659
    [No Abstract]   [Full Text] [Related]  

  • 53. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alopecia universalis unresponsive to treatment with tofacinitib: report of a case with a brief review of the literature.
    Salman A; Sarac G; Ergun T
    Dermatol Online J; 2017 Jul; 23(7):. PubMed ID: 29469706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Pharmacology profile and clinical findings of tofacitinib citrate (Xeljanz® tablet 5 mg)].
    Harada T; Nakamura H
    Nihon Yakurigaku Zasshi; 2014 Sep; 144(3):133-41. PubMed ID: 25213614
    [No Abstract]   [Full Text] [Related]  

  • 56. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic development in psoriasis.
    Sobell JM; Leonardi CL
    Semin Cutan Med Surg; 2014 Jun; 33(4 Suppl):S69-72. PubMed ID: 25268599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The use of tofacitinib in the treatment of inflammatory bowel disease.
    Weisshof R; Golan MA; Yvellez OV; Rubin DT
    Immunotherapy; 2018 Aug; 10(10):837-849. PubMed ID: 29701124
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of Tofacitinib in the treatment of inflammatory bowel disease.
    Nasonov EL; Abdulganieva DI; Fairushina IF
    Ter Arkh; 2019 Mar; 91(2):101-108. PubMed ID: 31094180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tofacitinib relieves symptoms of stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy caused by 2 de novo variants in TMEM173.
    Seo J; Kang JA; Suh DI; Park EB; Lee CR; Choi SA; Kim SY; Kim Y; Park SH; Ye M; Kwon SH; Park JD; Lim BC; Lee DH; Kang SJ; Choi M; Park SG; Chae JH
    J Allergy Clin Immunol; 2017 Apr; 139(4):1396-1399.e12. PubMed ID: 28041677
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.